Melnikov Mikhail, Rogovskii Vladimir, Boykо Alexey, Pashenkov Mikhail
Department of Neurology, Neurosurgery and Medical Genetics of Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997, Moscow, Russia.
Laboratory of Clinical Immunology, National Research Center Institute of Immunology of the Federal Medical-Biological Agency, 115478, Moscow, Russia.
J Neuroimmune Pharmacol. 2020 Mar;15(1):37-47. doi: 10.1007/s11481-019-09852-3. Epub 2019 Apr 23.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) with an autoimmune mechanism of development. Currently, one of the most promising directions in the study of MS pathogenesis are the neuroimmune interactions. Dopamine is one of the key neurotransmitters in CNS. Furthermore, dopamine is a direct mediator of interactions between the immune and nervous systems and can influence MS pathogenesis by modulating immune cells activity and cytokine production. Recent studies have shown that dopamine can enhance or inhibit the functions of innate and adaptive immune system, depending on the activation of different dopaminergic receptors, and can therefore influence the course of experimental autoimmune encephalomyelitis (EAE) and MS. In this review, we discuss putative dopaminergic therapeutics in EAE and MS with focus on Th17-cells, which are thought to play crucial role in MS pathogenesis. We suggest that targeting dopaminergic receptors could be explored as a new kind of disease-modifying treatment of MS. Graphical Abstract.
多发性硬化症（MS）是一种中枢神经系统（CNS）的慢性炎症性脱髓鞘疾病，其发病机制为自身免疫性。目前，MS发病机制研究中最有前景的方向之一是神经免疫相互作用。多巴胺是CNS中的关键神经递质之一。此外，多巴胺是免疫和神经系统之间相互作用的直接介质，可通过调节免疫细胞活性和细胞因子产生来影响MS的发病机制。最近的研究表明，多巴胺可根据不同多巴胺能受体的激活情况增强或抑制固有免疫和适应性免疫系统的功能，因此可影响实验性自身免疫性脑脊髓炎（EAE）和MS的病程。在本综述中，我们讨论了EAE和MS中可能的多巴胺能治疗方法，重点关注Th17细胞，其被认为在MS发病机制中起关键作用。我们建议将靶向多巴胺能受体作为一种新型的MS疾病改善治疗方法进行探索。图形摘要。
